New BD FACSDiscover™ S8 Cell Sorters to
Enable More Researchers to Push the Boundaries of
Discovery
FRANKLIN
LAKES, N.J., April 5,
2024 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
today announced the global commercial release of new cell sorters
that will enable more researchers in a broader range of fields,
including cell biology, cancer research and immunology, to reveal
insights that were previously invisible in traditional flow
cytometry experiments.
The new BD FACSDiscover™ S8 Cell Sorters feature BD
CellView™ Image Technology, profiled on the cover of the journal
Science in 2022, and BD SpectralFX™ Technology — bringing to
market breakthrough innovations in real-time imaging and spectral
flow cytometry. The three- and four-laser additions to the BD
FACSDiscover™ S8 Cell Sorter family complement the five-laser
instrument launched last year and provide scientists greater
access, options, and flexibility to incorporate real-time imaging
and spectral cell sorting technology in their labs.
"For my research in cellular biology, the instrument was
perfectly configured when it came to number of lasers and imaging
capabilities," said Daniel
Schraivogel, Ph.D., a research staff scientist at EMBL, who
estimates he had 600 hours working on the three-laser prototype.
"It has the same sorting speed and software capabilities as the
five-laser unit, making experiments extremely scalable on an
easy-to-use instrument."
Using the FACSDiscover™ S8 Cell Sorters, researchers can confirm
complex biological and spatial insights in real time, obtain
individual cell images and isolate desired cells based on visual
characteristics at high speeds, all within a simplified and easy to
use workflow. BD CellView™ Image Technology improves sort and
sample quality, bringing confidence to biological results and
saving researchers time and cost in their downstream applications.
This expedited time to insight expands capabilities for researchers
to transform research and cell-based therapeutic development across
numerous fields in drug discovery, immuno-oncology and
genomics.
"In flow cytometry, there are often 'suspect' populations where
cells are dead or dying, and doublets and cellular debris that can
impact the integrity of experiments," Schraivogel continued. "In
addition to the added value of spatial information that is needed
for many projects in cell biology, infection biology and functional
genomic screening, the imaging sorter allows us to better explore
our cell populations and is used to validate true single-cell
gating and sorting, to deliver better-quality cells and biological
outputs."
The family of BD FACSDiscover™ Cell Sorters will be featured at
upcoming conferences beginning with the American Association for
Cancer Research (AACR) Annual Meeting, April
5-10, and is now available to order through local sales
representatives. More information is available at
bdbiosciences.com/S8.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its more than
70,000 employees have a passion and commitment to help enhance the
safety and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or
Instagram @becton_dickinson.
Contacts:
|
|
Media:
|
Investors:
|
Troy Kirkpatrick
|
Adam Reiffe
|
VP, Public
Relations
|
Sr. Director, Investor
Relations
|
858.617.2361
|
201.847.6927
|
troy.kirkpatrick@bd.com
|
adam.reiffe@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-increases-access-to-cutting-edge-image-enabled-spectral-cell-sorters-302108936.html
SOURCE BD (Becton, Dickinson and Company)